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AbstrAct
Introduction National guidance for chronic obstructive 
pulmonary disease (COPD) suggests that self-management 
support be provided for patients. Our institution has 
developed a standardised, manual-based, supported self-
management programme: Self-Management Programme 
of Activity Coping and Education (SPACE for COPD(C)). 
SPACE was previously piloted on a 1-2-1 basis, delivered 
by researchers, to individuals with COPD. Discussions with 
stakeholders highlighted considerable interest in delivering 
the SPACE for COPD(C) intervention as a group-based 
self-management programme facilitated by healthcare 
professionals (HCPs) in primary care settings. The study 
aims are to explore the feasibility, acceptability and 
efficacy for the intervention to be delivered and supported 
by HCPs and to examine whether group-based delivery 
of SPACE for COPD(C), with sustained support, improves 
patient outcomes following the SPACE for COPD(C) 
intervention. 
Methods and analysis A prospective, multi-site, 
single-blinded randomised controlled trial (RCT) will be 
conducted, with follow-up at 6 and 9 months. Participants 
will be randomly assigned to either the control group 
(usual care) or intervention group (a six-session, group-
based SPACE for COPD(C)self-management programme 
delivered over 5 months). The primary outcome is change 
in COPD assessment test at 6 months. A discussion 
session will be conducted with HCPs who deliver the 
intervention to discuss and gain insight into any potential 
facilitators/barriers to implementing the intervention in 
practice. Furthermore, we will conduct semi-structured 
focus groups with intervention participants to understand 
feasibility and acceptability. All qualitative data will be 
analysed thematically.
Ethics and dissemination The project has received a 
favourable opinion from South Hampshire B Research 
Ethics Committee, REC reference: 14/SC/1169 and full 
R&D approval from the University Hospitals of Leicester 
NHS Trust: 152408. Study results will be disseminated 
through appropriate peer-reviewed journals, national 
and international respiratory/physiotherapy conferences, 
via the Collaboration and Leadership in Applied Health 
Research and Care and through social media.
Trial registration ISRCTN17942821; pre-results.
IntroductIon
Chronic obstructive pulmonary 
disease (COPD) is the third leading cause 
of death worldwide and is associated with 
considerable disability, impaired quality 
of life and high utilisation of healthcare 
resources.1 Symptoms and manifestations 
of the disease can be modified by adopting 
appropriate health behaviours including, 
but not limited to, exercise, physical activity, 
smoking cessation, anxiety management, 
breathing control, medication adherence 
and exacerbation management.2 Acknowl-
edging the importance of the role of the 
patient in adopting these behaviours, there 
has been a shift in attitude from a traditional 
paternalistic model of care towards a more 
collaborative approach for chronic disease 
management. The National Health Service 
(NHS) Five Year Forward View’s aim is for the 
NHS to become better at helping people to 
manage their own health by staying healthy, 
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Protocol
Strengths and limitations of this study
 ► The burden of chronic obstructive pulmonary 
disease  (COPD) is significant to both the health 
service and the individual. Supported self-
management is important, but options are limited 
for those with COPD. This study explores a group-
based supported self-management programme for 
individuals with COPD.
 ► This is a pragmatic trial where the study intervention 
(a group-based self-management support 
intervention for people with COPD) will be delivered 
and supported by healthcare professionals in 
community settings. The study has been designed 
to align with how the intervention might be delivered 
in routine clinical practice.
 ► Our follow-up period is 3 months post-intervention. 
Unfortunately, due to funding constraints, we are 
unable to carry out a longer term follow-up.
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making informed choices of treatment, managing condi-
tions and avoiding complications.3 Inevitably, the patient 
is predominantly responsible for administering their own 
care and making choices about health behaviours that 
will affect their outcomes. Self-management support aims 
to inform and support patients in making these choices. 
National and international guidelines for the manage-
ment of COPD suggest that self-management support 
should be provided for people with COPD, though at 
present evidence for how and when that support should 
be delivered is less robust.2
Reports in the literature describe programmes that 
have targeted interventions for patients who have been 
hospitalised with a COPD-related admission, often with 
the primary ambition of reducing future admissions.4 
These studies have had little impact on readmission. 
Arguably, the offer of supported self-management should 
be offered earlier in the disease trajectory. Other COPD 
self-management programmes beyond the UK have been 
described in a stable population. Although the models 
of care delivered are quite heterogeneous,5 with some 
programmes providing up to 2 years of weekly supervised 
exercise training and education.3 6–8 The infrastructure 
and resources required to provide such comprehensive 
support means they are unlikely to be deliverable to the 
breadth of the COPD population in the UK. In order to 
address this, we previously developed and tested a new 
self-management programme that offered a ‘light touch’ 
approach so that it could be provided on a larger scale.
A Self-Management Programme of Activity Coping 
and Education—SPACE for COPD(C)—aims to support 
people with COPD in managing day-to-day tasks, mini-
mise symptom burden, provoke health enhancing 
behaviour change and enhance emotional well-being. 
The programme is structured around the SPACE for 
COPD(C) manual, which combines both generic 
self-management skills and disease-specific tasks. Pilot 
testing assessed the feasibility and acceptability of the 
intervention to patients,9 and a fully powered randomised 
controlled trial assessed the efficacy of the intervention in 
primary care,10 powered for change in symptom burden 
measured by the self-reported Chronic Respiratory Ques-
tionnaire (CRQ-SR) dyspnoea domain at 6 months. In 
these studies, the SPACE for COPD(C) manual was intro-
duced to patients during an initial consultation with a 
healthcare professional (HCP) (using motivational inter-
viewing techniques), followed by two telephone calls 
during the subsequent 6 weeks. Secondary outcomes 
included other domains of the CRQ-SR, shuttle walking 
tests, disease knowledge, anxiety, depression, self-efficacy, 
smoking status and healthcare utilisation measured at 
baseline, 6 weeks and 6 months follow-up. Results demon-
strated significant short-term improvements in CRQ-SR 
dyspnoea, anxiety, fatigue and emotion scores, exer-
cise performance and disease knowledge. At 6 months, 
anxiety, exercise performance and smoking status 
outcomes remained significantly different between the 
intervention group and the usual care group, though 
there was no between-group difference in change in 
CRQ-SR dyspnoea.
Implementation focused work carried out following 
these studies with HCPs in primary care and local Clinical 
Commissioning Groups (CCGs), demonstrated consid-
erable interest in delivering the SPACE for COPD(C) 
intervention as a group-based intervention rather than 
on a one-to-one basis. The most common theoretical 
rationale underpinning delivery of group-based self-man-
agement support interventions is Social Cognitive 
Theory/Social Learning Theory.11 12 Bandura’s (1977, 
1997) social learning theory posits that behaviour is influ-
enced by beliefs about one’s ability to perform a particular 
behaviour (self-efficacy expectations), beliefs about the 
effectiveness of the behaviour (eg, the advantages and 
disadvantages of performing this behaviour; outcome 
expectations) and learning through social observation 
(including social norms, social support or pressure and 
the behaviours of others). Peer support and use of other 
patients as role models are approaches grounded in this 
theory and directly applicable to group-based self-man-
agement support interventions.
Delivery of SPACE for COPD(C) as a group-based 
intervention allows for several face-to-face contacts 
between patients and HCPs over a number of sessions. 
These contacts could be spread out further across a 
longer period, which may be more successful in main-
taining behaviour change. Furthermore, having earlier 
sessions closer together in time allows group cohesion 
to take place, an important factor in optimising group 
dynamics.13
The SPACE for COPD(C) intervention has also previ-
ously been delivered by a member of the research team 
rather than by existing clinical services. If the group-
based intervention were to be implemented in primary 
care following the current study, importance would be 
placed on delivery by HCPs in a format that is feasible 
and acceptable to HCPs, health service providers and to 
patients. Understanding how this intervention can be 
delivered within existing health services and identifying 
key barriers and facilitators to its implementation is an 
important next step in the development of this complex 
intervention.
Aims and objectives of the study
This study aims to:
1. Examine whether group-based delivery of SPACE for 
COPD(C), with sustained support, improves patient 
outcomes following the intervention compared with 
a control group;
2. Explore feasibility, acceptability and efficacy of the 
intervention to be delivered and supported by HCPs. 
This will be done by:
a. Exploring HCP’s experiences of delivering the 
intervention and identify any barriers to delivery 
in practice;
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Figure 1 Participant flow through the study.
b. Understanding, from the patient perspective, 
the feasibility and acceptability of the SPACE for 
COPD(C) intervention delivered by HCPs in a 
group-based community setting.
Methods/desIgn
study design
The trial is a prospective, multi-site, single (assessor) 
blinded randomised controlled trial comparing a 
community-based, HCP-led, group-based self-manage-
ment programme based on the SPACE for COPD(C) 
manual with usual care. The design of the study and flow 
of participants is described in figure 1. The study will 
be run across Leicestershire and Rutland, and a total of 
150 participants will be recruited (75 in the intervention 
group and 75 in the control group).
recruitment of participants
We will recruit participants with COPD, who will be 
identified from primary care (General Practice; GP) 
COPD registers and from patients who respond to a 
poster advertisement that will be displayed at GP prac-
tices and hospitals. We will also recruit participants from 
the following areas within the Respiratory Biomedical 
Research Unit at University Hospitals of Leicester:
 ► Those who have been involved in previous research 
trials who have agreed to be contacted again; or
 ► Those who were unsuitable for previous research trials 
but who agreed to be contacted about future research 
trials for which they might be eligible.
Participant invitation
Eligible individuals identified as having an established 
diagnosis of COPD are sent an invitation letter, a patient 
information sheet about the study and a reply slip. For 
those recruited directly from primary care, the invitation 
letters are sent by the primary care practice where the 
search was conducted. For those recruited from existing 
databases, the invitation is sent from the principal investi-
gator of the study. Individuals who are interested in taking 
part are asked to return a reply slip directly to the SPACE 
for COPD(C) research team. Interested participants are 
then contacted via their preferred contact method, and 
an appointment is arranged for a baseline visit.
eligibility criteria
Participants are eligible for the trial if they have:
 ► An established diagnosis of COPD as defined by 
The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) criteria.
Patients are excluded from participating in the trial if 
they are:
 ► Unable to participate in the exercise component 
of the SPACE for COPD(C) programme due to 
neurological, locomotive or psychiatric disability;
 ► Unable to participate in the exercise component 
of the SPACE for COPD(C) programme due to 
other comorbidities where exercise would be a 
contraindication (e.g., unstable angina);
 ► Unable to read/write English to the level of an 8 year 
old;
 ► Unwilling to be randomised;
 ► Previous participants of pulmonary rehabilitation or 
have received the SPACE for COPD(C) manual in the 
previous 12 months.
randomisation
Once participants have consented to take part in the 
study and spirometry has confirmed a COPD diagnosis, 
participants are randomised by an unblinded member 
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Table 1 SPACE for COPD(C) self-management programme 
session outline
Session 1 (week 1) Introduction to SPACE for COPD(C)
  1 Welcome and introductions
  2 Group responsibilities
  3 What does it mean to have COPD?
  4 What is self-management?
  5 How to use the SPACE for COPD(C) 
manual
  6 Goal setting
  7 Home activities for next session
  8 Summary and close
Session 2 (week 2) Introducing exercise and managing 
shortness of breath
  1 Welcome back
  2 Solution focused goal feedback
  3 Managing shortness of breath
  4 Introduction to the walking 
programme
  5 Goal setting
  6 Activities for next session
  7 Summary and close
Session 3 (week 4) Continuing exercise and saving 
energy
  1 Welcome back
  2 Solution focused goal feedback
  3 Saving your energy
  4 Strength training
  5 Goal setting
  6 Home activities for next session
  7 Group discussion
  8 Summary and close
Session 4 (week 8) Managing stress and emotions and 
the COPD action plan
  1 Welcome back
  2 Solution focused goal feedback
  3 Managing stress and emotions
  4 Action plans
  5 Goal setting
  6 Activities for next session
  7 Summary and close
Session 5 (week 14) Question and answer
  1 Welcome back
  2 Solution focused goal feedback
  3 Question and answer
  4 Goal setting
  5 Activities for next session
  6 Summary and close
Continued
of the study team using an online randomisation tool 
(sealed envelope).14 Individuals are randomised (1:1) 
to the control group or the intervention (SPACE for 
COPD(C) group-based self-management programme) 
group. The system randomises patients in random 
permuted blocks. This allows for the 1:1 ratio, but due 
to the random permuted blocks of 2, 4 or 6 ensures full 
randomisation. Simple randomisation has been chosen as 
there has been no requirement to stratify by age, gender, 
location or other variables. Participants are immediately 
informed of their allocated treatment by an unblinded 
member of the study team. Unblinding is permissible in 
the case of medical emergencies (eg, cardiac arrest) or 
patients being admitted to hospital for an exacerbation.
study interventions
Usual care (control group)
Participants in the control group will continue with any 
usual check-ups/reviews, and there will be no additional 
care provided or removed from their current access. If 
patients are referred to pulmonary rehabilitation in 
the duration of their time in the study, they will not be 
denied access to the programme; however, they will not 
be included in the final analysis due to the use of ‘inten-
tion-to-treat’ analysis. No additional advice, information 
or recommendations will be provided to participants in 
this group.
SPACE FOR COPD group-based self-management programme
Participants in the intervention group receive a SPACE 
for COPD(C) manual and are asked to attend the SPACE 
for COPD(C) group-based self-management programme 
usually within 1 month of their baseline appointment. 
The aim of the SPACE for COPD(C) programme is to 
support people with COPD in managing day-to-day tasks, 
minimise symptom burden, provoke health enhancing 
behaviour change and enhance emotional well-being. 
The programme is structured around the SPACE for 
COPD(C) manual, which combines both generic self-man-
agement skills and disease-specific tasks. The programme 
is facilitated by two trained HCPs (eg, physiotherapists, 
respiratory specialist nurses, occupational therapists and 
health psychologists) to groups of up to 10 participants 
and delivered through six 2-hour sessions, over a 5-month 
period. These sessions will be held at community venues, 
at times and locations to suit participants of the group to 
increase retention. Participants are liaised with in regards 
to preferences on timings and location of the group 
sessions to increase retention and engagement in the 
intervention. The content of the programme and accom-
panying self-management components15 are presented in 
tables 1 and 2. Participants are provided with a contact 
number for at least one of the facilitators throughout the 
course of the programme in case they have any further 
queries/are unable to attend any sessions.
Participants will also be asked to complete the exercise 
component of the manual at home in their own time. A 
full description of the rationale, development and efficacy 
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Session 6 (week 20) Keeping going from here
  1 Welcome back
  2 Solution focused goal feedback
  3 Hobbies
  4 Maintaining exercise
  5 Sharing success
  6 Summary and close
COPD, chronic obstructive pulmonary disease; SPACE for 
COPD(C), Self-Management Programme of Activity Coping and 
Education.
Table 1 Continued 
of the work underpinning the SPACE for COPD(C) 
manual is detailed elsewhere.9 The intervention will be 
offered over a period of 2 years (the duration of the active 
component of the intervention within the study) and will 
only be offered as part of the research, not routine prac-
tice within the community.
Intervention fidelity
Intervention facilitators are registered health profes-
sionals (physiotherapists, respiratory nurse specialists and 
health psychologists). In total, eight registered health 
professionals will be trained to deliver the SPACE for 
COPD(C) group-based intervention by two health 
psychologists.
All facilitators attended a 1-day training course to 
ensure that they understood the theories and philosophy 
underpinning the SPACE for COPD(C) group-based 
programme and the content and resources used within it. 
All facilitators were given a facilitator manual to support 
their delivery of the programme and given the opportu-
nity to practise delivering at least one activity from the 
manual during the training session.
Quality assurance
Quality assurance will be undertaken to assess delivery of 
intervention content and educational style. Intervention 
fidelity checklists for intervention facilitators and trained 
observers have been specifically designed for the study. 
Intervention facilitators will complete checklists at the 
end of each self-management group session, and one of 
the trainers will observe one session per self-management 
group, completing their own checklist. Intervention facil-
itators will receive written and verbal feedback from the 
trained assessor.
study outcomes
Data will be collected during baseline, 6-month and 
9-month appointments at the Leicester Respiratory 
Biomedical Research Unit by trained members of the 
study team. Data are collected following standardised 
operating procedures. Written informed consent is 
obtained from all participants prior to the commence-
ment of data collection. Details of all clinical assessments 
and outcome measures are provided in table 3. General 
practitioners are informed of patients’ participation in 
the trial and any relevant results. Any serious adverse 
events will be reported to the sponsor and patients’ ability 
to exercise safely will be monitored.
Primary outcome
The primary outcome is health status, as measured by the 
COPD Assessment Test (CAT)16 at 6 months post-base-
line. This measure was chosen due to ease of use in 
clinical practice compared with the Chronic Respiratory 
Questionnaire (as used in the previous RCT). The CAT 
is a validated, short (eight items) and simple patient 
completed questionnaire and assesses globally the impact 
of COPD (cough, sputum, dyspnoea and chest tightness) 
on health status. The CAT is scored 0–5 with a range of 
0–40; scores of 0–10, 11–20, 21–30, 31–40 represent mild, 
moderate, severe or very severe clinical impact, respec-
tively.
secondary outcomes
Clinical measures
Exercise capacity
Maximal exercise capacity will be measured with the 
incremental shuttle walk test (ISWT) according to the 
protocol of Singh et al17 using a 10 m course. According to 
current standards, an individual change of at least 47.5 m 
is considered clinically important.18 Endurance capacity 
will be measured with the endurance shuttle walk test 
using a 10 m course and a walking speed of 85% of the 
maximal ISWT walking speed.19
Physical activity
Physical activity is assessed using physical activity moni-
tors. The ‘Bodymedia Sensewear’ (APC Cardiovascular, 
UK) activity monitor is a biaxial accelerometer that can 
report a number of parameters including step count and 
energy expenditure. We will also use these data to assess 
compliance to the physical activity recommendation of 
undertaking at least 150 min of moderate intensity physical 
activity per week in bouts of at least 10 mins. Participants are 
asked to wear the activity monitor on the back of their right 
arm for seven consecutive days (24 hours a day if possible) 
following their baseline, 6-month and 9-month visits.
Questionnaires
Health-related quality of life (HRQOL)
HRQoL data will be measured using the European Quality 
of Life-5 Dimensions (EQ-5D20 21). The EQ-5D is a stan-
dardised questionnaire that was developed for use as a 
measure of health outcomes and defines health in terms of 
five dimensions: mobility, self-care, usual activities, pain or 
discomfort and anxiety or depression.
Self-reported Chronic Respiratory Questionnaire
Disease-specific HRQoL will be measured by the self-ad-
ministered standardised CRQ-SR.22 An individual change 
of at least 0.5/domain (dyspnoea, fatigue, emotional func-
tioning and mastery) is considered clinically important.23 
6 Bourne CLA, et al. BMJ Open 2017;7:e014463. doi:10.1136/bmjopen-2016-014463
Open Access 
Ta
b
le
 2
 
Ta
xo
no
m
y 
co
m
p
on
en
ts
 p
re
se
nt
 in
 t
he
 S
PA
C
E
 fo
r 
C
O
P
D
(C
) f
ac
ili
ta
to
r 
m
an
ua
l, 
el
ab
or
at
io
n 
of
 t
he
 t
ec
hn
iq
ue
s 
un
d
er
 e
ac
h 
co
m
p
on
en
t,
 d
ire
ct
 e
xa
m
p
le
s 
fr
om
 t
he
 
S
PA
C
E
 fo
r 
C
O
P
D
(C
) f
ac
ili
ta
to
r 
m
an
ua
l a
nd
 t
he
 d
os
e 
of
 t
he
 c
om
p
on
en
t
Ta
xo
no
m
y 
co
m
p
o
ne
nt
E
la
b
o
ra
ti
o
n
E
xa
m
p
le
s 
fr
o
m
 t
he
 S
PA
C
E
 f
o
r 
C
O
P
D
(C
) f
ac
ili
ta
to
r 
m
an
ua
l (
d
os
e)
A
2.
 In
fo
rm
at
io
n 
ab
ou
t 
av
ai
la
b
le
 r
es
ou
rc
es
P
ar
tic
ip
an
ts
 a
re
 p
ro
vi
d
ed
 w
ith
 in
fo
rm
at
io
n 
th
ro
ug
ho
ut
 t
he
 p
ro
gr
am
m
e 
(e
ve
ry
 
se
ss
io
n)
.
A
3.
 P
ro
vi
si
on
 o
f/
ag
re
em
en
t 
on
 s
p
ec
ifi
c 
cl
in
ic
al
 a
ct
io
n 
p
la
ns
 a
nd
/o
r 
re
sc
ue
 
m
ed
ic
at
io
n
S
es
si
on
 4
: A
ct
io
n 
p
la
ns
 (s
es
si
on
 4
 o
nl
y)
.
A
6.
 P
ra
ct
ic
al
 s
up
p
or
t 
w
ith
 a
d
he
re
nc
e 
(m
ed
ic
at
io
n 
or
 b
eh
av
io
ur
al
)
W
al
ki
ng
 a
nd
 s
tr
en
gt
h 
tr
ai
ni
ng
 d
ia
rie
s 
ar
e 
p
ro
vi
d
ed
 fo
r 
p
ar
tic
ip
an
ts
 a
nd
 d
is
cu
ss
ed
 d
ur
in
g 
se
ss
io
ns
.
W
al
ki
ng
 a
nd
 s
tr
en
gt
h 
tr
ai
ni
ng
 d
ia
rie
s 
ar
e 
p
ro
vi
d
ed
 fo
r 
p
ar
tic
ip
an
ts
 a
nd
 
d
is
cu
ss
ed
 d
ur
in
g 
so
lu
tio
n 
fo
cu
se
d
 g
oa
l f
ee
d
b
ac
k 
at
 t
he
 b
eg
in
ni
ng
 o
f 
se
ss
io
ns
 3
–6
 (s
es
si
on
s 
3–
6)
.
A
8.
 S
af
et
y 
ne
tt
in
g
P
ar
tic
ip
an
ts
 a
re
 a
b
le
 t
o 
ca
ll 
p
ro
gr
am
m
e 
fa
ci
lit
at
or
s 
b
et
w
ee
n 
se
ss
io
ns
 if
 n
ee
d
ed
P
ar
tic
ip
an
ts
 a
re
 p
ro
vi
d
ed
 w
ith
 c
on
ta
ct
 d
et
ai
ls
 fo
r 
p
ro
gr
am
m
e 
fa
ci
lit
at
or
s 
w
ho
 
th
ey
 c
an
 c
al
l i
f n
ee
d
ed
 (t
hi
s 
is
 a
 c
on
st
an
t 
th
ro
ug
ho
ut
 t
he
 p
ro
gr
am
m
e)
.
A
11
. T
ra
in
in
g/
re
he
ar
sa
l f
or
 p
ra
ct
ic
al
 s
el
f-
m
an
ag
em
en
t 
ac
tiv
iti
es
In
cl
ud
in
g:
 
►
m
an
ag
in
g 
sh
or
tn
es
s 
of
 b
re
at
h
 
►
sa
vi
ng
 y
ou
r 
en
er
gy
S
es
si
on
 2
: M
an
ag
in
g 
sh
or
tn
es
s 
of
 b
re
at
h 
(s
es
si
on
 2
 o
nl
y)
.
S
es
si
on
 3
: S
av
in
g 
yo
ur
 e
ne
rg
y 
(s
es
si
on
 3
 o
nl
y)
.
A
12
. T
ra
in
in
g/
re
he
ar
sa
l i
n 
p
sy
ch
ol
og
ic
al
 
st
ra
te
gi
es
In
cl
ud
in
g:
 
►
go
al
 s
et
tin
g 
(in
cl
ud
in
g 
ac
tio
n 
p
la
nn
in
g)
 
►
so
lu
tio
n 
fo
cu
se
d
 g
oa
l f
ee
d
b
ac
k
 
►
p
ro
b
le
m
 s
ol
vi
ng
 
►
se
lf-
re
w
ar
d
 a
nd
 s
oc
ia
l r
ew
ar
d
 
►
m
an
ag
in
g 
st
re
ss
 a
nd
 e
m
ot
io
ns
G
oa
l s
et
tin
g 
ac
tiv
ity
 (i
nc
lu
d
in
g 
ac
tio
n 
p
la
nn
in
g)
 a
nd
 s
ol
ut
io
n 
fo
cu
se
d
 g
oa
l 
fe
ed
b
ac
k 
(o
nc
e 
ev
er
y 
se
ss
io
n)
.
P
ro
b
le
m
 s
ol
vi
ng
 (t
hi
s 
is
 a
 c
on
st
an
t 
th
ro
ug
ho
ut
 t
he
 p
ro
gr
am
m
e)
.
S
es
si
on
 4
: M
an
ag
in
g 
st
re
ss
 a
nd
 e
m
ot
io
ns
 (s
es
si
on
 4
 o
nl
y)
.
A
13
. S
oc
ia
l s
up
p
or
t
In
cl
ud
in
g:
 
►
p
ra
ct
ic
al
 s
up
p
or
t
 
►
em
ot
io
na
l s
up
p
or
t
P
ar
tic
ip
an
ts
 a
re
 e
nc
ou
ra
ge
d
 t
o 
sh
ar
e 
ex
p
er
ie
nc
es
, a
d
vi
ce
, i
d
ea
s 
an
d
 s
up
p
or
t 
ea
ch
 o
th
er
 (t
hi
s 
is
 a
 c
on
st
an
t 
th
ro
ug
ho
ut
 t
he
 p
ro
gr
am
m
e)
.
A
14
. L
ife
st
yl
e 
ad
vi
ce
 a
nd
 s
up
p
or
t
In
cl
ud
in
g:
 
►
in
tr
od
uc
tio
n 
to
 t
he
 w
al
ki
ng
 p
ro
gr
am
m
e
 
►
st
re
ng
th
 t
ra
in
in
g
 
►
ho
b
b
ie
s
 
►
m
ai
nt
ai
ni
ng
 e
xe
rc
is
e
S
es
si
on
 2
: I
nt
ro
d
uc
tio
n 
to
 t
he
 w
al
ki
ng
 p
ro
gr
am
m
e 
(s
es
si
on
 2
 o
nl
y)
.
S
es
si
on
 3
: S
tr
en
gt
h 
tr
ai
ni
ng
 (s
es
si
on
 3
 o
nl
y)
.
S
es
si
on
 6
: H
ob
b
ie
s 
(s
es
si
on
 6
 o
nl
y)
.
S
es
si
on
 6
: M
ai
nt
ai
ni
ng
 e
xe
rc
is
e 
(s
es
si
on
 6
 o
nl
y)
.
S
PA
C
E
 fo
r 
C
O
P
D
(C
), 
S
el
f-
m
an
ag
em
en
t 
P
ro
gr
am
m
e 
of
 A
ct
iv
ity
 C
op
in
g 
an
d
 E
d
uc
at
io
n.
 7Bourne CLA, et al. BMJ Open 2017;7:e014463. doi:10.1136/bmjopen-2016-014463
Open Access
Table 3 Details of study clinical assessments and outcome measures at all appointments
Baseline appointment (blinded and unblinded 
study team members)
6-month appointment (blinded 
study team member)
9-month appointment (blinded 
or unblinded study team 
member)
Consent
Collection of demographic details and medical history
Blood pressure
Spirometry
Randomisation*
Questionnaires (CAT, EQ-5D, CRQ-SR, BCKQ, PAM, 
HADS)*
Shuttle walking tests* (intervention participants only): 
2xISWT; 1xESWT
Participants given Senswear activity monitor to wear 
for 7 days*
Check consent
Questionnaires (CAT, EQ-5D, CRQ-
SR, BCKQ, PAM, HADS)
Shuttle walking tests†
Participants given Senswear activity 
monitor to wear for 7 days
Check consent
Questionnaires (CAT, EQ-5D, 
CRQ-SR, BCKQ, PAM, HADS)
Shuttle walking tests
Participants given Senswear 
activity monitor to wear for 
7 days
*Carried out by an unblinded member of the study team.
†ESWT carried out by an unblinded member of the study team.
BCKQ, Bristol COPD Knowledge Questionnaire; CAT, COPD Assessment Test; CRQ-SR, Chronic Respiratory Questionnaire; EQ-5D, 
European Quality of Life-5 Dimensions; ESWT, endurance shuttle walking test; ISWT, incremental shuttle walking test; HADS, Hospital Anxiety 
and Depression Questionnaire.; PAM, Patient Activation Measure.
There is both an initial and follow-up version depending on 
time of administration.
Anxiety and depression
Depression and anxiety will be measured using the Hospital 
Anxiety and Depression (HADS) Scale to produce inde-
pendent subscales for anxiety and depression.24 The HADS 
is a self-report rating scale of 14 items on a 4-point Likert 
scale range (0–3). The HADS is a validated and a widely 
used questionnaire for screening for the separate dimen-
sions of anxiety and depression and possible occurrence 
of anxiety and depression from patients25 and the general 
population.26 It measures anxiety and depression (seven 
items for each subscale). Cronbach’s coefficient was 0.884, 
which indicates good reliability. Published cut-off scores 
for clinically relevant indications of depression and anxiety 
recommend a score of 8 for each subscale.27
Patient activation
Patient activation (participants’ knowledge, skill and 
confidence for managing their own health and health-
care) will be measured using the Patient Activation 
Measure.28 This is a 13-item patient-reported measure 
that has been validated in the UK as a powerful and reli-
able measure of patient activation. Participants indicate 
their level of agreement on a four-point scale (strongly 
disagree to strongly agree) and responses are added to 
yield a raw score between 13 and 52. The raw score is 
calibrated to an activation score between 0 and 100 (the 
higher the score the higher the level of activation), which 
is then used to classify participants into one of four levels 
of activation (level 1: low activation; level 4: high activa-
tion).
COPD knowledge
The Bristol COPD Knowledge Questionnaire will be used 
to understand patients’ informational requirements and 
understanding and their knowledge base of COPD.29 
The questionnaire is comprehensive and goes into detail, 
regarding various aspects of COPD, for example epidemi-
ology, signs and symptoms and exacerbations and treatment.
Outcomes to assess feasibility and acceptability of trial parameters
We will use the following outcomes to assess the feasibility 
and acceptability of trial parameters:
Screening
Defined as the number of packs sent out to patients from 
GP practices and assessed for eligibility using inclusion/
exclusion criteria by a study researcher.
Eligibility
Calculated by dividing number of people screened for 
eligibility by those who meet the inclusion criteria.
Consent
Defined as the proportion of people with COPD who met 
inclusion criteria, and were therefore eligible, who went 
on to consent in writing to participate in the study.
Group characteristics
Group characteristics (eg, age, gender, GOLD stage, 
Medical Reseach Council (MRC) dyspnoea grade, exer-
cise capacity, physical activity) will be compared between 
completers and non-completers.
Retention
Defined as the number of participants who remain in the 
study and do not drop-out.
Study completion
Defined by the number of participants who complete the 
CAT at 6-months. Completion rates will be calculated at 
baseline, 6-month and 9-month follow-up.
Intervention adherence and completion rates
This will be measured by summing the total number 
of self-management programme sessions attended by 
participants allocated to the intervention group. We will 
also look at the average group size across each of the 
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six self-management programme sessions and compare 
with the number of participants allocated to each of the 
self-management programme groups.
Qualitative data collection
Those participants allocated to the intervention group 
are invited to take part in qualitative focus groups at 
the end of the SPACE for COPD(C) intervention. Focus 
groups have been chosen due to their generation of 
information on collective views and the meanings that lie 
behind those views. The aim of the focus groups will be to 
understand participants’ experiences of the group-based 
self-management programme. More specifically, the data 
we collect will inform:
 ► Acceptability and usefulness of the programme to 
participants in this format and over this time period;
 ► The content of the intervention;
 ► Approaches to recruitment.
Focus groups will be conducted with each self-man-
agement programme group, with between 3 and 10 
participants (number dependent on each group size). 
This difference in participant numbers allows for partic-
ipant opinions to be gathered even if a small group is 
encountered (eg, due to drop-out). Although three is a 
very small number for a focus group, it allows all partic-
ipant opinions to be gathered, regardless of group size. 
Participants will be familiar with one another (which can 
help facilitate discussion or the ability to challenge each 
other comfortably) as they have attended multiple group 
sessions together. Purposive sampling will be employed 
to recruit intervention participants. Audio-recorded 
focus group discussions (approximately 60 min) will be 
conducted face-to-face between each participant group, 
an experienced interviewer and an observer/note-taker. 
Focus groups will be carried out at the end of the last 
group session for participant ease, as discussed with study 
patient representatives. We will prompt participants allo-
cated to each self-management group of the focus group 
discussion prior to the last session in the attempt to 
gain experiences from as many participants as possible, 
regardless of the number of sessions attended in total. 
Focus groups will be transcribed verbatim by a profes-
sional transcriber, with identifiable information removed. 
Focus group questions have been devised based on rele-
vant literature and experience of the team.
HCPs delivering the SPACE for COPD self-management 
support intervention will be invited to participate in a 
meeting to discuss aspects of feasibility and acceptability, 
such as gaining insight into any potential facilitators/
barriers to implementing the intervention in practice 
(and derive practical recommendations for doing so). 
Minutes will be taken during the discussion and anony-
mised.
data analysis
Study power
The power calculation was based on the primary outcome 
at 6 months.30 31 To detect a mean±SD between-group 
difference of 2.5±5.0 in the change in CAT with 80% 
power, 60 people per group are required (α=0.05, 
two tailed). In anticipation of a possible 25% attrition 
rate, the total sample size was increased to 75 per group 
(150 in total).
Quantitative analysis
This will primarily be completed on an intention-to-treat 
analysis. All quantitative data will be assessed for normality 
and analysed using appropriate parametric and non-para-
metric statistics (eg, within and between measures t-tests 
and analyses of variance); statistical significance will be 
set at p=0.05. Secondary per protocol analyses will be 
carried out.
A post hoc analysis will be carried out, which will 
exclude patients in either arm that received pulmonary 
rehabilitation as part of their usual care. We would antic-
ipate that patients who participate within the study will 
not require pulmonary rehabilitation. However, due to 
pulmonary rehabilitation being a part of ‘best’ usual care, 
this will not be withheld from the patient.
Quantitative data for all outcomes will be transcribed 
from the case report form (CRF) onto an electronic data-
base. A statistical software package will be used to carry out 
quantitative analyses. Predictive analytics software (SPSS; 
Statistical Package for the Social Sciences) will be used 
to analyse the data, the licence for which is provided by 
University Hospitals of Leicester NHS Trust. Continuous 
variables will be presented as mean and SD or median and 
IQR, and categorical data will be presented as frequencies 
and percentages. Data will be checked for normality and 
appropriate parametric and non-parametric tests will be 
used. Any baseline differences will be adjusted for. Any 
missing data will be imputed, and both intention-to-treat 
and per-protocol analyses will be conducted.
We have not secured funding for a healthcare utilisation 
analysis but would anticipate further CLAHRC (Collabo-
ration and Leadership in Applied Health Research and 
Care) funding if the trial is clinically effective.
Qualitative analysis
The focus groups will be analysed using Thematic Anal-
ysis32 supported by NVivo software (V.9). This approach 
follows six distinct stages: familiarisation with data, 
generating initial codes, searching for themes, reviewing 
themes, defining and naming themes; and producing the 
report. The psychologist and the physiotherapist will carry 
out initial coding and a sample of interviews will be coded 
by another member of the team to ensure consistency 
and to enhance interpretive authenticity. Throughout 
the data analysis, the team will meet to discuss and review 
emerging themes and search for accounts that provide 
contesting views of the same phenomena or identify 
different phenomena. Our patient representatives will 
be invited to comment on our (anonymised) findings 
throughout the analysis process to ensure interpretations 
made by researchers stay close to the direct experience of 
patients.33
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All patient information that is collected during the 
course of the research will be kept strictly confidential. 
Any information about the patient who leaves the hospital 
will have their name and address removed. Participants 
will not be identified in any subsequent written material. 
Results will be reported in such a way that completely 
preserves confidentiality.
ethIcs And dIsseMInAtIon
ethics
The trial is sponsored by the University Hospitals of 
Leicester NHS Trust (study number 152408), and ethical 
approval was granted by the Hampshire B Research Ethics 
Committee (REC reference: 14/SC/1169). Protocol 
amendments will be approved by the ethics committee 
and regulatory authorities as per current guidelines and 
will be communicated to relevant parties by the study 
team.
dissemination
We plan to publish the results of the study in peer-reviewed 
journals and present them at appropriate national and 
international respiratory and physiotherapy conferences. 
Social media will be used to disseminate information and 
summaries of results to a wider population.
The CLAHRC East Midlands is a large organisation 
that strives to improve health outcomes in the population 
across the East Midlands through delivering high-quality, 
world class research. This organisation will be used to 
further disseminate results within the East Midlands. We 
also hope to provide a summary of results to the study 
participants. Furthermore, we plan to hold a participant 
dissemination day towards the end of the study. This will 
enable participants to contribute to the final report and 
other result dissemination activities.
The institution also has an active and dynamic public 
involvement group for pulmonary and cardiovascular 
rehabilitation. The group will be used to create and coor-
dinate strategies for further disseminating the results into 
the public domain.
The study may also be subject to internal and further 
external audits to ensure safety of the trial.
conclusIon
The importance of self-management is widely acknowl-
edged, and opportunities should be maximised from 
the time of diagnosis through to more severe disease. 
Opportunities to improve self-management skills should 
be embedded in a pulmonary rehabilitation programme. 
In the future, there may be an opportunity to explore 
the value of the SPACE for COPD(C) programme along-
side rehabilitation, or indeed, an alternative for those 
unwilling or unable to attend. However, for those with 
milder disease, there is no provision for a structured 
supported self-management programme in the UK. 
Evidence suggests that the SPACE for COPD(C) package 
is effective when delivered on an individual basis.10 This 
study examines its effectiveness as a group-based inter-
vention in the community, as an alternative supported 
self-management strategy, which importantly allows 
patient choice.
Protocol version
11 18.11.2015. Study started on 02/2015, and ends in 
06/2017. Recruitment was 20 months.
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